Research Explainer
What is a GLP-1 medicine?
GLP-1 is short for glucagon-like peptide-1. Here is a plain-language starting point—what these medicines are, which ones public guidance names, and what is still being studied.
What the name means
GLP-1 stands for glucagon-like peptide-1. GLP-1 receptor agonists are a class of medicines that, according to the World Health Organization, help lower blood sugar, support weight loss, and reduce the risk of heart and kidney complications in people with type 2 diabetes.[1]
Which medicines are discussed
WHO’s 2025 obesity guideline gives recommendations for three agents used in the long-term treatment of obesity in adults: liraglutide, semaglutide, and tirzepatide.[1]
Part of a wider approach
WHO describes GLP-1 therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from health professionals—noting that medicines alone will not solve obesity.[1]
What’s still being studied
WHO made its recommendation conditional, citing limited data on long-term efficacy and safety, maintenance and discontinuation, costs, and health-system readiness.[1]
Product quality matters
FDA says unapproved versions of these medicines do not undergo FDA review for safety, effectiveness, or quality before they are marketed.[2]
What this does not answer
It does not tell any one person whether a GLP-1 medicine is right for them. Individual decisions and support needs belong with a qualified healthcare professional.
This page is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.
Sources
- [1]WHO issues global guideline on the use of GLP-1 medicines in treating obesityWorld Health OrganizationRead the source (opens in a new tab)
- [2]FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossU.S. Food & Drug AdministrationRead the source (opens in a new tab)
